O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radio

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radio

Item

http://www.wikidata.org/entity/Q44838622

Q44838622

about

Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review Polymeric drug delivery for the treatment of glioblastoma Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents BCNU/PLGA microspheres: a promising strategy for the treatment of gliomas in mice.Feasibility evaluation of hypofractionated radiotherapy with concurrent temozolomide in elderly patients with glioblastoma.The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.MGMT promoter methylation correlates with an overall survival benefit in Chinese high-grade glioblastoma patients treated with radiotherapy and alkylating agent-based chemotherapy: a single-institution study.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain.The future of high-grade glioma: Where we are and where are we going.Extracellular RNAs: development as biomarkers of human disease.O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.Ribozyme-Spherical Nucleic Acids Rapid regression of glioblastoma following carmustine wafer implantation: A case report The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.The role of Gliadel wafers in the treatment of high-grade gliomas.Pharmacologic therapies for malignant glioma: a guide for clinicians.Delivery of local therapeutics to the brain: working toward advancing treatment for malignant gliomas.The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.Molecularly based management of gliomas in clinical practice.ExRNA in Biofluids as Biomarkers for Brain Tumors.Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas.Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.Is the prognostic significance of O6-methylguanine- DNA methyltransferase promoter methylation equally important in glioblastomas of patients from different continents? A systematic review with meta-analysis.MGMT promoter methylation in non-neoplastic brain.MGMT promoter methylation in plasma of glioma patients receiving temozolomide.Prognosis of glioblastoma with faint MGMT methylation-specific PCR product.The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis.Players of 'hypoxia orchestra' - what is the role of FMISO?Immunohistochemical evaluation of O6 -methylguanine DNA methyltransferase (MGMT) expression in 117 cases of glioblastoma.

P2860

Q26739012-25B57B67-E681-463B-AD34-1C8C89573995 Q27010046-6C2EEC30-A758-4F07-A3C3-79377A0DE1C2 Q28078486-806BE88A-2A03-4761-8B20-496577625C47 Q28273012-1B277A6E-24D0-4D7C-9ADE-563F23D9A1B6 Q30782637-6CDB5257-4E20-47E7-A878-9B48333AC4D8 Q33433682-20BE7F3E-80DB-4840-BA97-1E716EDD6315 Q33578787-2BFF1687-47E5-4516-A8AE-C77C6DDA1CC2 Q34166477-70CEDD2A-9049-4212-9C1D-40C2D554097D Q34478948-F84C2338-5395-4B15-8152-BF8340590A1D Q34525981-CD1B042C-92AB-45B6-A6A3-AB64A6568D19 Q35114090-F0256B40-AC66-42CD-A38D-CF28A1FDB7F1 Q36006446-38CD4830-80BC-4A27-BFA1-14CA25F4BEC4 Q36288503-2A572862-54B0-40DA-9ADB-1298130B92A9 Q36299167-5008145C-72E8-4CA2-9BB5-3BB216F00D2F Q36338490-8ED92208-732C-448A-B5CD-D7A122464BE4 Q37001342-B4992936-E102-4327-8BDC-48B74A7F1B11 Q38093776-89E6C933-D778-4AE0-B389-3D62C93DEA4E Q38162925-CBA0FB3C-1951-47EB-A6CE-6EABEE5294E0 Q38268897-943A02D1-895D-46BA-8189-618FCC5FC9AA Q38411351-5D92E8A4-FB3D-46E3-A2D0-7865FC9874ED Q38546470-6B617FD6-2971-47CA-95B2-1AD601960BBF Q38551010-FD9B5E35-EB89-4E01-B5F0-223FDA942F8D Q38781031-9F07E91B-2D0A-4059-943B-8AE82EFD4F5E Q39046974-3BB79D46-89C8-4355-95FF-FC88CE450EA5 Q39273311-F7F4BAF8-2516-436D-9D56-737FDE469618 Q41459741-F99F8381-FC6E-40B0-9DC2-C5796EBDDFB8 Q42290698-BC4B088B-73D7-492B-A76F-631353CA75D9 Q42364418-D7F6C2B7-1889-466F-AF49-6BBA969FF48D Q44440342-4C4D3C45-C86F-415B-B43C-71D2879E7274 Q45088198-02273898-976A-46F3-99A0-80103CF7E089 Q48137109-F3E04BCF-1320-45E3-9549-CCB38FD10320 Q52606179-5D834117-35D7-4BEE-BA04-40982C8A463D Q52939507-BA16D78E-7BAC-4259-A49B-D2B8A2069A5E Q55461295-FBE1A765-7761-499B-8FEE-559D386F1D1A

P2860

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radio

Item

http://www.wikidata.org/entity/Q44838622

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

O(6) -methylguanine-DNA methyl ...... tial surgery followed by radio

@en

type

Item

label

O(6) -methylguanine-DNA methyl ...... tial surgery followed by radio

@en

prefLabel

O(6) -methylguanine-DNA methyl ...... tial surgery followed by radio

@en

P1476

O(6) -methylguanine-DNA methyl ...... tial surgery followed by radio

@en

P2093

Anne Vital

http://www.w3.org/2001/XMLSchema#string

Audrey Emmanuelle Dugué

http://www.w3.org/2001/XMLSchema#string

Emmanuèle Lechapt-Zalcman

http://www.w3.org/2001/XMLSchema#string

Evelyne Emery

http://www.w3.org/2001/XMLSchema#string

Françoise Chapon

http://www.w3.org/2001/XMLSchema#string

Guénaëlle Levallet

http://www.w3.org/2001/XMLSchema#string

Jean-Sébastien Guillamo

http://www.w3.org/2001/XMLSchema#string

Marie-Danièle Diebold

http://www.w3.org/2001/XMLSchema#string

Philippe Colin

http://www.w3.org/2001/XMLSchema#string

Philippe Peruzzy

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.

P304

4545-4554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27441

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Menei

Myriam Bernaudin

P577

2012-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22359215

http://www.w3.org/2001/XMLSchema#string

P921

biodegradation

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radio

about

P2860

P2860

O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radio

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921